Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

P Moreau, SK Kumar, J San Miguel, F Davies… - The Lancet …, 2021 - thelancet.com
Summary This Policy Review presents the International Myeloma Working Group's clinical
practice recommendations for the treatment of relapsed and refractory multiple myeloma …

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

J Hillengass, S Usmani, SV Rajkumar… - The lancet …, 2019 - thelancet.com
Recent advances in the treatment of multiple myeloma have increased the need for accurate
diagnosis of the disease. The detection of bone and bone marrow lesions is crucial in the …

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma …

JG Berdeja, D Madduri, SZ Usmani, A Jakubowiak… - The Lancet, 2021 - thelancet.com
Background CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene
autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation …

Initial clinical activity and safety of BFCR4350A, a FcRH5/CD3 T-cell-engaging bispecific antibody, in relapsed/refractory multiple myeloma

AD Cohen, SJ Harrison, A Krishnan… - Blood, The Journal …, 2020 - ashpublications.org
Introduction: New targets and treatment modalities are needed for multiple myeloma (MM).
Fc receptor-homolog 5 (FcRH5) is a type I membrane protein that is expressed on B cells …

[HTML][HTML] Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma

A Chari, MC Minnema, JG Berdeja… - … England Journal of …, 2022 - Mass Medical Soc
Background G protein–coupled receptor, family C, group 5, member D (GPRC5D) is an
orphan receptor expressed in malignant plasma cells. Talquetamab, a bispecific antibody …

[HTML][HTML] Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE …

T Martin, SZ Usmani, JG Berdeja, M Agha… - Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
PURPOSE CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of
ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory …

Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma

PG Richardson, S Trudel, R Popat… - … England Journal of …, 2023 - Mass Medical Soc
Background Despite recent progress, multiple myeloma remains incurable. Mezigdomide is
a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal …

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

EM Stein, G Garcia-Manero, DA Rizzieri… - Blood, The Journal …, 2018 - ashpublications.org
Abstract Pinometostat (EPZ-5676) is a first-in-class small-molecule inhibitor of the histone
methyltransferase disrupter of telomeric silencing 1-like (DOT1L). In this phase 1 study …

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple …

SK Kumar, JG Berdeja, R Niesvizky, S Lonial… - The Lancet …, 2014 - thelancet.com
Background The combination of bortezomib, lenalidomide, and dexamethasone is a highly
effective therapy for newly diagnosed multiple myeloma. Ixazomib is an investigational, oral …

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial

AJ Yee, WI Bensinger, JG Supko, PM Voorhees… - The Lancet …, 2016 - thelancet.com
Background Histone deacetylase (HDAC) inhibitors are an important new class of
therapeutics for treating multiple myeloma. Ricolinostat (ACY-1215) is the first oral selective …